Cost-Effectiveness of Pazopanib: An Example of Improved Transparency and Accessibility of Industry-Sponsored Economic Evaluations through Publication in Peer-Reviewed Journals

J. Beca; K.K.W. Chan

doi:10.3747/co.22.2741

You are currently viewing a new version of our website. To view the old version click .

Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..

Editorial

1 August 2016

Cost-Effectiveness of Pazopanib: An Example of Improved Transparency and Accessibility of Industry-Sponsored Economic Evaluations through Publication in Peer-Reviewed Journals

and

Pharmacoeconomics Research Unit, Cancer Care Ontario, and Canadian Centre for Applied Research in Cancer Control, Toronto, ON, Canada

Sunnybrook Odette Cancer Centre, Canadian Centre for Applied Research in Cancer Control, and Department of Medicine, University of Toronto, Toronto, ON, Canada

Author to whom correspondence should be addressed.

Curr. Oncol.2016, 23(4), 327-329;https://doi.org/10.3747/co.22.2741

Version Notes

Order Reprints

Excerpt

Note: In lieu of an abstract, this is an excerpt from the first page.

We congratulate Amdahl et al. on publishing their paper about the cost-effectiveness of pazopanib compared with sunitinib in metastatic renal cell carcinoma (mrcc) in Canada. [...]

Article Metrics

Citations

Article Access Statistics

Journal Statistics

Multiple requests from the same IP address are counted as one view.

Approach to Fever Assessment in Ambulatory Cancer Patients Receiving Chemotherapy: A Clinical Practice Guideline

HPV Vaccines? Still Needed